Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

Completed · Phase 2

Conditions studied: Pandemic H5N1 Influenza

In brief

Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in children.

Key facts

Study ID
NCT01776554
Run by
Novartis Vaccines
People needed
662
Starts
2013-01-01
Expected to finish
2014-06-01
Last updated by the study team
2019-01-16

Who can join

Age: 1 and older, up to 17. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.